GHK-Cu: Research, Clinical Evidence & Copper Peptides

Overview

GHK-Cu is the complex formed by the GHK tripeptide with copper(II). GHK itself is glycyl-L-histidyl-L-lysine, a naturally occurring human tripeptide. The two names are not interchangeable in every sentence: one names the peptide; the other names the copper chelate.^4,5

This hub orients the evidence. There is a substantial biochemical and preclinical literature, widespread cosmetic interest, and some human dermatologic research. Rigorous randomized clinical trials are few. A 2026 systematic review found 20 studies, of which 18 were preclinical and only 2 were randomized trials.¹

That is a different profile from a drug with a mature clinical program, and also different from a peptide whose human evidence is almost absent. The useful question here is what sits in cells, what sits in animals, what sits in people, and what is only marketing.

GHK versus GHK-Cu

Treating both as if they were the same thing hides a real chemical difference. Copper is not an ornament on the name: it changes the identity of the complex under study. The detail is in What Is GHK-Cu.

What a copper peptide is

“Copper peptide” is a broad descriptive category. It can cover more than one peptide–copper complex. GHK-Cu is one specific complex, sometimes also called copper tripeptide-1 in cosmetic nomenclature. That commercial label does not make every “copper peptide” serum the same object of study.⁷

A commercial serum is not, by name, equivalent to a trial formulation. Formulation, vehicle, and route matter. That limitation returns throughout the cluster.

Evidence map

Main research areas

• Extracellular-matrix biology, including collagen- and glycosaminoglycan-related work in culture.^6,4
• Fibroblast biology and tissue remodeling, mainly in mechanistic reviews.⁵
• Wound models and angiogenesis in the preclinical literature.⁴
• Skin-aging research and cosmetic use, with human clinical evidence still limited.^7,1

Those are laboratory and applied-research areas, not demonstrated human indications. Mechanism is developed in proposed mechanisms and extracellular-matrix biology.

What clinical evidence exists

The randomized trial we can cite as a primary publication is Miller and colleagues, 2006: a topical regimen after CO2 laser resurfacing. Thirteen participants completed the study. Objective computer analysis and blinded evaluation did not find statistically significant advantages for earlier erythema resolution, objective wrinkle improvement, or overall skin quality. A patient-reported overall skin-quality satisfaction measure did favor the GHK-Cu regimen.²

That is not summarized as “GHK-Cu clinically proved to reduce wrinkles.” Objective and subjective outcomes stay separate. The detail is in what the clinical evidence actually shows for skin.

The 2026 systematic review included 20 studies: 18 preclinical and 2 randomized trials. The second randomized trial is not identified in this source system as an independent primary publication; a trial citation is not invented here from the review.¹

NCT07437586 is a Phase 2 registry record of a topical GHK-Cu gel versus vehicle on standardized punch-biopsy wounds. The status reviewed on 1 September 2026 is Recruiting. No results are posted. A recruiting trial is not a demonstrated treatment.³

The human inventory is in human clinical studies. The wound and repair line is in tissue-repair research.

Regulatory / compounding status in the U.S.

GHK-Cu is not an FDA-approved drug. In the 22 April 2026 update, FDA stated that GHK-Cu — except for injectable routes of administration — was removed from Category 1 because nominations were withdrawn, and that GHK-Cu for injectable routes was removed from Category 2 for the same reason. The Agency also stated that it intends to consult the Pharmacy Compounding Advisory Committee before the end of February 2027 regarding potential inclusion on the 503A bulks list.⁸

That is not approval, not final inclusion, not final exclusion, and not Mexican law. The immunogenicity concern FDA has described refers to the compounded injectable route, not to topical skin evidence. The detail is in FDA and compounding status.⁹

What we do not know

• Which formulation, vehicle, or delivery system, if any, reliably reproduces a clinical endpoint.^1,7
• Whether a subjective finding in 13 people replicates with objective endpoints in a larger trial.²
• What NCT07437586 will show; the registry has not posted results.³
• How the planned PCAC consultation before the end of February 2027 will resolve.⁸
• GHK-Cu is not established as a “powerful anti-aging peptide,” a “skin-regeneration peptide,” or a wound treatment. Those phrases are marketing language, not an established scientific classification.

Explore research

Six pages cover distinct intents: identity and copper-peptide terminology; matrix mechanisms; skin clinical evidence; wound and repair; the human inventory; and FDA/compounding status.

Analytical documentation

A certificate of analysis describes lot identity and purity. It does not demonstrate a clinical effect on skin or on a wound. See the GHK-Cu certificate archive and, if you are looking for the research material, the product page.